Genus plc (GENSF)
USD 25.1
(0.0%)
USD 25.1
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 228.2 Million USD | 16.43% |
| 2023 | 248.78 Million USD | 12.25% |
| 2022 | 221.63 Million USD | 46.65% |
| 2021 | 151.13 Million USD | 18.06% |
| 2020 | 128 Million USD | -1.3% |
| 2019 | 129.68 Million USD | -18.62% |
| 2018 | 159.35 Million GBP | -3.55% |
| 2017 | 165.22 Million GBP | 7.2% |
| 2016 | 154.13 Million GBP | 93.15% |
| 2015 | 79.8 Million GBP | 9.92% |
| 2014 | 72.6 Million GBP | 15.97% |
| 2013 | 62.6 Million GBP | -5.01% |
| 2012 | 65.9 Million GBP | -18.94% |
| 2011 | 81.3 Million GBP | -14.96% |
| 2010 | 95.6 Million GBP | -9.13% |
| 2009 | 105.2 Million GBP | 34.53% |
| 2008 | 78.2 Million GBP | -29.1% |
| 2007 | 110.3 Million GBP | -12.81% |
| 2006 | 126.5 Million GBP | 44758.16% |
| 2005 | 282 Thousand GBP | -53.39% |
| 2004 | 605 Thousand GBP | -89.07% |
| 2003 | 5.53 Million GBP | -31.05% |
| 2002 | 8.02 Million GBP | -28.09% |
| 2001 | 11.16 Million GBP | -12.28% |
| 2000 | 12.72 Million GBP | 1839.48% |
| 1999 | 656 Thousand GBP | -51.23% |
| 1998 | 1.34 Million GBP | 85.77% |
| 1997 | 724 Thousand GBP | 14380.0% |
| 1996 | 5000.00 GBP | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 FY | 288.51 Million USD | 15.97% |
| 2024 Q3 | 228.2 Million GBP | 0.88% |
| 2024 Q1 | 273.59 Million GBP | 15.41% |
| 2024 Q2 | 287.95 Million GBP | 0.0% |
| 2024 Q4 | 228.2 Million GBP | 0.0% |
| 2023 Q3 | 217.9 Million GBP | -16.16% |
| 2023 Q4 | 248.78 Million USD | 14.17% |
| 2023 Q2 | 259.9 Million USD | 8.47% |
| 2023 FY | 248.78 Million USD | 12.25% |
| 2023 Q1 | 239.6 Million GBP | 15.97% |
| 2022 Q1 | 170 Million GBP | 12.49% |
| 2022 Q2 | 170 Million GBP | 0.0% |
| 2022 Q3 | 206.6 Million GBP | 21.53% |
| 2022 Q4 | 206.6 Million GBP | 0.0% |
| 2022 FY | 221.63 Million USD | 46.65% |
| 2021 Q3 | 128.7 Million GBP | -10.33% |
| 2021 Q4 | 151.13 Million GBP | 17.43% |
| 2021 Q1 | 123.6 Million GBP | -3.44% |
| 2021 Q2 | 143.52 Million GBP | 16.12% |
| 2021 FY | 151.13 Million USD | 18.06% |
| 2020 FY | 128 Million USD | -1.3% |
| 2020 Q1 | 122.1 Million GBP | -5.85% |
| 2020 Q4 | 128 Million GBP | 2.65% |
| 2020 Q3 | 124.69 Million GBP | -6.24% |
| 2020 Q2 | 133 Million GBP | 8.93% |
| 2019 Q3 | 105.8 Million GBP | 2.32% |
| 2019 FY | 129.68 Million USD | -18.62% |
| 2019 Q1 | 103.39 Million GBP | -15.8% |
| 2019 Q2 | 103.4 Million GBP | 0.0% |
| 2019 Q4 | 129.68 Million GBP | 22.58% |
| 2018 Q1 | 125.69 Million GBP | -2.56% |
| 2018 Q3 | 122.8 Million GBP | -2.31% |
| 2018 Q4 | 122.8 Million GBP | 0.0% |
| 2018 FY | 159.35 Million GBP | -3.55% |
| 2018 Q2 | 125.7 Million GBP | 0.0% |
| 2017 Q4 | 129 Million GBP | 0.0% |
| 2017 FY | 165.22 Million GBP | 7.2% |
| 2017 Q3 | 129 Million GBP | -8.9% |
| 2017 Q2 | 141.6 Million GBP | 0.0% |
| 2017 Q1 | 141.6 Million GBP | 20.0% |
| 2016 Q1 | 102.6 Million GBP | 28.57% |
| 2016 Q3 | 118.7 Million GBP | 15.69% |
| 2016 Q4 | 118 Million GBP | -0.59% |
| 2016 FY | 154.13 Million GBP | 93.15% |
| 2016 Q2 | 102.6 Million GBP | 0.0% |
| 2015 Q2 | 85.3 Million GBP | 0.0% |
| 2015 Q1 | 85.3 Million GBP | 17.49% |
| 2015 FY | 79.8 Million GBP | 9.92% |
| 2015 Q3 | 79.8 Million GBP | -6.45% |
| 2015 Q4 | 79.8 Million GBP | 0.0% |
| 2014 Q1 | 89 Million GBP | 42.17% |
| 2014 FY | 72.6 Million GBP | 15.97% |
| 2014 Q4 | 72.6 Million GBP | 0.0% |
| 2014 Q2 | 89 Million GBP | 0.0% |
| 2014 Q3 | 72.6 Million GBP | -18.43% |
| 2013 Q2 | 64.5 Million GBP | 0.0% |
| 2013 Q3 | 62.6 Million GBP | -2.95% |
| 2013 FY | 62.6 Million GBP | -5.01% |
| 2013 Q4 | 62.6 Million GBP | 0.0% |
| 2012 Q2 | 80.3 Million GBP | 0.0% |
| 2012 FY | 65.9 Million GBP | -18.94% |
| 2012 Q4 | 65.9 Million GBP | 0.0% |
| 2011 Q4 | 81.3 Million GBP | 0.0% |
| 2011 FY | 81.3 Million GBP | -14.96% |
| 2011 Q2 | 84.1 Million GBP | 0.0% |
| 2010 Q4 | 95.6 Million GBP | 0.0% |
| 2010 Q2 | 105.7 Million GBP | 0.0% |
| 2010 FY | 95.6 Million GBP | -9.13% |
| 2009 Q4 | 105.2 Million GBP | 0.0% |
| 2009 FY | 105.2 Million GBP | 34.53% |
| 2009 Q2 | 95.3 Million GBP | 0.0% |
| 2008 FY | 78.2 Million GBP | -29.1% |
| 2008 Q4 | 78.2 Million GBP | 0.0% |
| 2008 Q2 | 92.8 Million GBP | 0.0% |
| 2007 Q4 | 110.3 Million GBP | 0.0% |
| 2007 Q2 | 122.6 Million GBP | 0.0% |
| 2007 FY | 110.3 Million GBP | -12.81% |
| 2006 Q3 | - GBP | 0.0% |
| 2006 FY | 126.5 Million GBP | 44758.16% |
| 2006 Q1 | - GBP | 0.0% |
| 2005 FY | 282 Thousand GBP | -53.39% |
| 2005 Q1 | - GBP | 0.0% |
| 2005 Q3 | 282 Thousand GBP | 0.0% |
| 2004 FY | 605 Thousand GBP | -89.07% |
| 2004 Q3 | 605 Thousand GBP | 0.0% |
| 2004 Q1 | - GBP | 0.0% |
| 2003 FY | 5.53 Million GBP | -31.05% |
| 2002 FY | 8.02 Million GBP | -28.09% |
| 2001 FY | 11.16 Million GBP | -12.28% |
| 2000 FY | 12.72 Million GBP | 1839.48% |
| 1999 FY | 656 Thousand GBP | -51.23% |
| 1998 FY | 1.34 Million GBP | 85.77% |
| 1997 FY | 724 Thousand GBP | 14380.0% |
| 1996 FY | 5000.00 GBP | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 8000.00 USD | -2852400.0% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -12899.301% |
| Qrons Inc. | 80 Thousand USD | -285150.0% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -1023.474% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -133171.039% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -991.396% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -389040.889% |
| Mesoblast Limited | 100.29 Million USD | -127.529% |
| Marizyme, Inc. | 667.12 Thousand USD | -34106.278% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | -37.383% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -4139958.055% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -10225.792% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -16165.911% |
| IMV Inc. | 27.39 Million USD | -732.89% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -4105.304% |
| MultiCell Technologies, Inc. | 36.43 USD | -626406707.576% |
| ONE Bio Corp. | 592.19 Thousand USD | -38434.409% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | -310.343% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -10151.572% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -18477.601% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -41047.514% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -901911.937% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -11920.218% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -70769.565% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 97.97% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -152033.333% |
| Enzolytics Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -138872.626% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | -1386.258% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -5121084.919% |
| Genscript Biotech Corporation | 287.12 Million USD | 20.524% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -180578.057% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -99424.185% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -99250.867% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -2661.375% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -85807.354% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -21447268.421% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -152425.833% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -152425.833% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -161743.972% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -2818.173% |
| SYBLEU INC | 300 Thousand USD | -75966.667% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -61734.607% |
| International Stem Cell Corporation | 445 Thousand USD | -51180.899% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -2700.0% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -49834.354% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -19555.469% |
| PureTech Health plc | 18.25 Million USD | -1150.411% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -152033.333% |
| IXICO plc | 275 Thousand USD | -82881.818% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -1827.528% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -767.384% |
| CSL Limited | 11.23 Billion USD | 97.97% |
| Cellectis S.A. | 36.21 Million USD | -530.193% |